GlassScriptPhysician profile
Logan Vander Woude
NPI 1972037018
$30,316.47
in general payments reported to CMS, 2019-2025
25 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $22.98 · 2021: $842 · 2022: $735 · 2023: $1,158 · 2024: $1,772 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $14K · Consulting Fee: $7,400 · Food and Beverage: $4,768 · Travel and Lodging: $2,371 · Gift: $48.11 · Honoraria: $38.86 · Education: $2.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $13,808.63 |
| Consulting Fee | $7,400.00 |
| Food and Beverage | $4,767.79 |
| Travel and Lodging | $2,371.34 |
| Gift | $48.11 |
| Honoraria | $38.86 |
| Education | $2.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $14,593.91 | 2019-2025 | Argos, Wavelight Refractive Suite, Rocklatan |
| Bausch & Lomb Americas INC. | $10,673.21 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| New World Medical,INC. | $998.62 | 2023-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Abbvie INC. | $906.52 | 2022-2025 | Xen Glaucoma Treatment System, Durysta, Lumigan |
| Johnson & Johnson Surgical Vision, INC. | $593.41 | 2021-2025 | Tecnis Iol, Tecnis Iol |
| Sight Sciences, INC. | $363.28 | 2021-2023 | Omni Surgical System |
| Rxsight INC | $295.90 | 2024-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Glaukos Corporation | $288.51 | 2022-2024 | Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Ocular Therapeutix, INC. | $241.07 | 2021-2024 | Dextenza |
| Dompe US, INC. | $207.73 | 2022-2025 | Oxervate |
| Biotissue Holdings INC. | $156.43 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $149.10 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $141.92 | 2021-2025 | Acthar |
| Allergan, INC. | $124.99 | 2021 | |
| Mallinckrodt Enterprises LLC | $117.04 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $103.96 | 2021 | |
| Aerie Pharmaceuticals, INC. | $100.13 | 2021 | |
| Boston Scientific Corporation | $64.38 | 2025 | Watchman Flx |
| Amgen INC. | $44.20 | 2025 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $38.73 | 2022-2025 | Eylea, Eylea Hd |
| Ani Pharmaceuticals, INC. | $24.76 | 2024 | Purified Cortrophin Gel |
| Harrow Eye, LLC | $24.70 | 2024 | Iheezo |
| Oyster Point Pharma, INC. | $22.97 | 2023 | Tyrvaya |
| Carl Zeiss Meditec Cataract Technology INC. | $22.06 | 2023 | |
| Sun Pharmaceutical Industries INC. | $18.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Vander Woude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.